$MMSI (Merit Medical Systems, Inc.)

$MMSI {{ '2016-03-28T15:26:05+0000' | timeago}} • Announcement

$MMSI said it received notification of substantial equivalence from the FDA for the Corvocet Biopsy System, intended for use in obtaining core biopsy samples from the liver, kidney, prostate, breast, lung and various other soft tissue tissue tumors. Corvocet is scheduled to be introduced in the US over the next 30 days or so.

$GILD {{ '2017-07-27T19:04:57+0000' | timeago}} • Webcast

For HCV, $GILD’s total revenues in the US were $1.9Bil in 2Q17, down 17% YoY and up 13% sequentially. The QoQ increase was primarily due to a change in inventory and the timing of patient starts. In Europe, total HCV revenue was $591MM, down 24% YoY and up 21% from 1Q17.

$GILD {{ '2017-07-27T19:00:11+0000' | timeago}} • Webcast

$GILD is seeing strong uptake of its TAF-based regimens in the US and Europe. In the US, total HIV and HBV revenues were $2.6Bil for 2Q17, up 19% YoY and up 10% sequentially. In Europe, total HIV and HBV revenues were $732MM, down 3% YoY and up 5% sequentially. The YoY decrease was driven by negative foreign exchange.

$CELG {{ '2017-07-27T18:53:16+0000' | timeago}} • Announcement

Biotech heavyweight $CELG reported strong profit in 2Q17, helped by higher product sales. Net income of $1.06Bil and diluted EPS of $1.31, surged 77% and 75%, respectively. Total revenue rose 19% to $3.3Bil, while  net product sales alos increased 19% for the recent quarter. Celgene's earnings grew 26% to $1.82 per share on an adjusted basis.

$GILD {{ '2017-07-27T18:32:52+0000' | timeago}} • Announcement

$GILD declared a cash dividend of $0.52 per share of common stock for 3Q17, payable on September 28, 2017, to stockholders of record on September 15, 2017.

$CELG {{ '2017-07-27T14:01:16+0000' | timeago}} • Infographic

$CELG Celgene Earnings AlphaGraphic: Q2 2017 highlights

$BAX {{ '2017-07-27T13:25:22+0000' | timeago}} • Announcement

Healthcare products provider $BAX has completed the acquisition of pharmaceutical company Claris Injectables. The $625MM transaction was financed through a combination of cash and debt. The company expects the acquisition to be modestly accretive to its adjusted earnings in 2017, and increasingly accretive thereafter.

$CYH {{ '2017-07-27T12:33:35+0000' | timeago}} • Announcement

Hospital operator $CYH said it expects 2Q17 operating revenue to be about $4.1Bil, lower than $4.6Bil recorded last year. The company sees a net loss of $137MM or $1.22 per share for the quarter, compared to the $1.431Bil loss recorded in 2Q16. Adjusted EBITDA is estimated at $435MM, compared to $563MM a year earlier.

$GILD {{ '2017-07-26T21:10:46+0000' | timeago}} • Infographic

$GILD Gilead Sciences Earnings AlphaGraphic: Q2 2017 Highlights

$GILD {{ '2017-07-26T20:37:51+0000' | timeago}} • Announcement

$GILD revised its FY17 guidance. The company now expects net product sales to be $24-25.5Bil in FY17. Non-HCV product sales are expected to be $15.5-16Bil while HCV product sales are expected to be $8.5-9.5Bil. Adjusted product gross margin is expected to be 86-88% in FY17.

$GILD {{ '2017-07-26T20:33:53+0000' | timeago}} • Announcement

$GILD's total product sales for 2Q17 were $7Bil compared to $7.7Bil for 2Q16. Product sales were $5Bil in the US, $1.4Bil in Europe and $665MM in other locations during 2Q17. Antiviral product sales were $6.4Bil and Other product sales were $607MM for 2Q17.

$GILD {{ '2017-07-26T20:29:32+0000' | timeago}} • Announcement

$GILD posted a slight decrease in 2Q17 results. Net income was $3.1Bil or $2.33 per share compared to $3.5Bil or $2.58 per share in 2Q16. Adjusted net income was $3.4Bil or $2.56 per share in 2Q17. Total revenues were $7.1Bil compared to $7.8Bil in the prior-year period.

$BAX {{ '2017-07-26T12:58:04+0000' | timeago}} • Announcement

$BAX anticipates 2020 adjusted EPS of $3.25-3.40. $BAX also lifted its cash flow expectations for 2020 and now sees operating cash flow of about $2.65Bil. Capital expenditures are expected to total $650MM in 2020, resulting in free cash flow generation of about $2Bil, an increase of $250MM versus prior guidance.

$BAX {{ '2017-07-26T12:56:58+0000' | timeago}} • Announcement

As a result of ongoing business transformation efforts designed to accelerate performance, $BAX lifted its 2020 financial outlook. $BAX expects sales growth of 4% on a compounded annual basis from 2016 to 20202 and now sees adjusted operating margin in 2020 of about 20% as compared to previous guidance of 17-18%.

$BAX {{ '2017-07-26T12:55:25+0000' | timeago}} • Announcement

$BAX expects 3Q17 sales growth of about 4% on a reported basis, about 5% on a constant currency basis and about 6% operationally. The company expects earnings from continuing operations, before special items, of $0.58-0.60 per diluted share.

$BAX {{ '2017-07-26T12:54:23+0000' | timeago}} • Announcement

$BAX lifted 2017 EPS from continuing operations, before special items, guidance to $2.34-2.40 from $2.20-2.28. This guidance assumes the closure of the company's proposed acquisition of Claris Injectables, to be complete by the end of July 2017.

$BAX {{ '2017-07-26T12:52:56+0000' | timeago}} • Announcement

$BAX now expects 2017 sales growth of about 3% on a reported basis, about 4% on constant currency basis and about 5% operationally. Previously, the company had predicted sales growth of about 1-2% on a reported basis or 2-3% on a constant currency basis.

$BAX {{ '2017-07-26T12:46:39+0000' | timeago}} • Announcement

$BAX's renal sales totaled $968MM, comparable to the prior year on reported basis and up 3% on both a constant currency basis and operational basis. Growth was driven by increased sales for in-center hemodialysis (HD) products in the US, international acute renal care sales and global sales of peritoneal dialysis (PD) therapies.

$BAX {{ '2017-07-26T12:45:36+0000' | timeago}} • Announcement

$BAX's global sales for Hospital Products totaled $1.6Bil in 2Q17, rising 1% on reported, 2% on constant currency and 4% operationally. This was driven by continued strength in US fluid systems business, favorable demand for parenteral nutrition therapies and pre-mixed injectable, as well as for select anesthesia and critical care products.

$BAX {{ '2017-07-26T12:42:25+0000' | timeago}} • Announcement

$BAX reported a 78% dip in 2Q17 earnings due to last year's net realized gains from exchange of its retained shares of Baxalta and contribution to its U.S. pension fund. Net income dropped to $265MM or $0.48 per share from $1.21Bil or $2.19 per share last year. Net sales rose 1% to $2.61Bil. Adjusted EPS grew 37% to $0.63.

$CELG {{ '2017-07-25T20:43:29+0000' | timeago}} • Announcement

$CELG, which is set to release its earnings results on July 27, settles a lawsuit filed by Beverly Brown, a former saleswoman of the drugmaker, by paying a total of $280MM. The lawsuit claimed that Celgene used illegal marketing tactics to promote its cancer drugs Thalomid and Revlimid among doctors.

Recent Transcripts

GILD (Gilead Sciences Inc.)
Wednesday, July 26 2017 - 8:30pm
BAX (Baxter International Inc.)
Wednesday, July 26 2017 - 12:30pm
MMM (3M Company)
Tuesday, July 25 2017 - 1:00pm
CRY (CryoLife Inc.)
Tuesday, July 25 2017 - 12:00pm
MDT (Medtronic plc)
Thursday, May 25 2017 - 12:00pm
VRML (Vermillion, Inc.)
Thursday, May 11 2017 - 12:30pm
NXTM (Nxstage Medical, Inc.)
Tuesday, May 9 2017 - 1:00pm
ATRS (Antares Pharma Inc.)
Tuesday, May 9 2017 - 12:30pm
OFIX (Orthofix International N.V.)
Thursday, May 4 2017 - 8:30pm
TFX (Teleflex Incorporated)
Thursday, May 4 2017 - 12:00pm
MASI (Masimo Corporation)
Wednesday, May 3 2017 - 8:30pm
WMGI (Wright Medical Group N.V.)
Wednesday, May 3 2017 - 8:30pm
LIVN (LivaNova PLC)
Wednesday, May 3 2017 - 1:00pm
AMRN (Amarin Corporation plc)
Wednesday, May 3 2017 - 12:00pm
KTWO (K2M Group Holdings, Inc.)
Tuesday, May 2 2017 - 9:00pm
GILD (Gilead Sciences Inc.)
Tuesday, May 2 2017 - 8:30pm
CYH (Community Health Systems, Inc.)
Tuesday, May 2 2017 - 4:00pm
MMSI (Merit Medical Systems, Inc.)
Thursday, April 27 2017 - 9:00pm
RMD (ResMed Inc.)
Thursday, April 27 2017 - 8:30pm
SPNC (The Spectranetics Corporation)
Thursday, April 27 2017 - 8:30pm

AlphaGraphics you may like